150 related articles for article (PubMed ID: 6357802)
1. Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
Scarffe JH; Anderson H; Palmer MK; Crowther D
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1361-4. PubMed ID: 6357802
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment serum beta 2-microglobulin in multiple myeloma.
Brenning G; Simonsson B; Källander C; Ahre A
Br J Haematol; 1986 Jan; 62(1):85-93. PubMed ID: 3510657
[TBL] [Abstract][Full Text] [Related]
3. Serum beta 2-microglobulin at remission and relapse in patients with multiple myeloma.
Brenning G; Wibell L; Bergström R
Eur J Clin Invest; 1985 Oct; 15(5):242-7. PubMed ID: 3935453
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
5. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
Pelliniemi TT; Irjala K; Mattila K; Pulkki K; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
Blood; 1995 Feb; 85(3):765-71. PubMed ID: 7530507
[TBL] [Abstract][Full Text] [Related]
6. Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.
Cuzick J; De Stavola BL; Cooper EH; Chapman C; MacLennan IC
Br J Haematol; 1990 Aug; 75(4):506-10. PubMed ID: 2119793
[TBL] [Abstract][Full Text] [Related]
7. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
8. Beta 2 microglobulin in multiple myeloma.
Alexanian R; Barlogie B; Fritsche H
Am J Hematol; 1985 Dec; 20(4):345-51. PubMed ID: 3907332
[TBL] [Abstract][Full Text] [Related]
9. Serum beta 2-microglobulin: a real improvement in the management of multiple myeloma?
van Dobbenburgh OA; Rodenhuis S; Ockhuizen T; Weltevreden E; Houwen B; Fidler V; Meijer S; Marrink J
Br J Haematol; 1985 Dec; 61(4):611-20. PubMed ID: 3910076
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
[TBL] [Abstract][Full Text] [Related]
11. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
Baldini L; Radaelli F; Chiorboli O; Fumagalli S; Cro L; Segala M; Cesana BM; Polli EE; Maiolo AT
Cancer; 1991 Jul; 68(1):62-7. PubMed ID: 2049754
[TBL] [Abstract][Full Text] [Related]
12. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
Kraj M; Maj S; Pogłód R; Rostkowska J
Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
[TBL] [Abstract][Full Text] [Related]
13. Serum beta-2-microglobulin in patients with multiple myeloma treated with alpha interferon.
Murakami H; Ogawara H; Morita K; Saitoh T; Matsushima T; Tamura J; Sawamura M; Karasawa M; Miyawaki S; Schimano S; Satoh S; Tsuchiya J
J Med; 1997; 28(5-6):311-8. PubMed ID: 9604789
[TBL] [Abstract][Full Text] [Related]
14. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
15. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
16. Factors useful for predicting survival of myeloma patients in everyday practice. A 10-year study of 148 patients older than 55 years.
Chombart B; Lemoussu LG; Eschard JP; Ackah-Miezan S; Novella JL; Brochot P; Pignon B; Etienne JC
Joint Bone Spine; 2005 Dec; 72(6):544-9. PubMed ID: 16226477
[TBL] [Abstract][Full Text] [Related]
17. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
18. Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.
Shimizu K; Kamiya O; Hamajima N; Mizuno H; Kobayashi M; Hirabayashi N; Takeyama H; Kato R; Kawashima K; Nitta M
Jpn J Cancer Res; 1990 Dec; 81(12):1320-7. PubMed ID: 2126002
[TBL] [Abstract][Full Text] [Related]
19. [Value of the determination of beta-2-microglobulin in the monitoring of myeloma. Apropos of 290 determinations].
Kaltwasser P; Sauger F; Le Loet X; Pasquis P; Monconduit M; Deshayes P
Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):359-63. PubMed ID: 6179150
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
Scudla V; Vavrdová V; Budíková M; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]